US Center for Disease Control review paper

Wednesday January 25, 2023

Destiny Pharma plc
(“Destiny Pharma” or the “Company”)

US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections

Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in general, following a series of announcements and two publications in leading medical journals in recent weeks.

Destiny is developing its novel XF-73 Nasal gel for the prevention of post-surgical infections. XF-73 is the lead drug candidate developed from Destiny Pharma’s XF platform and it is initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which can cause significant complications and increased healthcare costs in the hospital setting.

Dr. Yuri Martina, Chief Medical Officer of Destiny Pharma, said: “The Centre for Disease Control’s announcement clearly recognizes the need for new and effective decolonization agents and their importance for public health. They have made a clear call to simplify the pathway to regulatory approval and suggested the need for establishing new surrogate endpoints. Destiny Pharma views this as a very encouraging shift in the agency’s thinking that could be very supportive to our clinical  development of XF-73 Nasal.

“Furthermore, it is important to note the two new papers in such respected journals as the Journal of the American Medical Association and the New England Journal of Medicine, which have both underlined the importance of decolonization in preventing post-surgical infections and complications. Both papers have also elaborated on the substantial impact of post-surgical infections for patients and the potential for long-term debilitation and life-threatening consequences. At Destiny Pharma, we are committed to progressing the Phase 3 clinical development of our XF-73 Nasal gel targeting nasal decolonization and delivering a new product to prevent post-surgical infections and the resulting complications for patients in hospitals around the world.”

CDC announcement underlines the need for new decolonization agents

On 28th December 2022, the CDC released a Broad Agency Announcement, following up on a CDC-FDA workshop held in August 2022, that clearly underlines the need for new decolonization agents, which have largely been missing in recent years, leading to an important gap in the public health portfolio of infection prevention. The Company believes this adds further support to its Phase 3 clinical strategy for XF-73 Nasal gel targeting nasal decolonization prior to surgery and indicates that regulators are increasingly aware of the importance and value of decolonization to help prevent infections. Prevention is better than cure.

Two major review publications supporting decolonization published

In January 2023, two important review papers on the key role of decolonization were published, by The Journal of the American Medical Association (“JAMA”) and The New England Journal of Medicine (“NEJM”).

The Journal of the American Medical Association

The JAMA review was authored by Dr. Deverick J. Anderson and colleagues at Duke Center for Antimicrobial Stewardship and Infection Prevention of the Duke University School of Medicine. In this review, the authors underline the following key points:

  • A large number of patients experience post-surgical infections, often with severe morbidity and complications.
  • Surgical site infections are among the most prevalent health care-acquired infections and result in significant costs, potentially reaching US$10 billion per year.
  • Approximately 70-95% of surgical sites infections are caused by the patient’s endogenous flora. Among these, aureus is the most common cause of infection.
  • Several risk factors are associated with surgical site infection. Some can be modified, but others cannot be impacted.
  • Nasal decolonization has shown a substantial reduction in surgical site infections and especially in high-risk surgeries like orthopaedic and cardiothoracic procedures.
  • Nasal decolonization should be achieved as close to surgery as possible, as this is the time when it is most effective.
  • The current standard of care requires a fairly long procedure and consequently a significant amount of coordination.

The New England Journal of Medicine

The NEJM review was authored by Dr. Robin Patel from the Division of Clinical Microbiology, Department of Medicine at the Mayo Clinic, and focuses on the topic of periprosthetic joint infection (PJI). In this paper, Dr. Patel discusses the importance of prevention to reduce the burden of PJI and its impact on the healthcare system and the patients. Importantly, Dr. Patel underlines the following critical points:

  • PJI is a serious complication of orthopaedic surgery with an average frequency of 2.3%.
  • PJI complication is costly and burdensome for the patient and the healthcare system. The author estimates additional cost of US$391,000 for a PJI of the hip.
  • PJI is associated with extended hospital stay, less-than-ideal success rates, decreased quality of life, pain, and high mortality.
  • Reducing risks factors is not always possible and some risk factors cannot be influenced.
  • A major impact on reducing PJI incidence can be achieved by implementing proper decolonization protocols.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440

Optimum Strategic Communications 
Mary Clark / Nick Bastin / Eleanor Cooper
+44 (0) 203 922 0891

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500

Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090

MC Services AG
Anne Hennecke / Andreas Burckhardt

Stern IR – US
Janhavi Mohite

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit

Notes to editors

  • On 28th December 2022, CDC released a Broad Agency Announcement calling for alternative clinical outcomes and/or surrogate endpoints to facilitate clinical trials for decolonization drugs
  • On the 17th of January 2023, a paper published in The Journal of American Medical Association (JAMA) underlines the importance of decolonization and nasal decolonization from S. aureus to prevent post-surgical site infection
  • On the 19th of January 2023, the New England Medical Journal (NEJM) published a paper discussing the issue of periprosthetic joint infection (PJI), its outcomes and implications and its prevention through the reduction of risk factors and proper decolonization protocols

Forward looking statements

Certain information contained in this announcement, including any information as to the Group’s strategy, plans or future financial or operating performance, constitutes “forward-looking statements”. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “aims”, “plans”, “predicts”, “may”, “will”, “seeks”, “could”, “targets”, “assumes”, “positioned” or, “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the Group’s results of operations, financial condition, prospects, growth, strategies and the industries in which the Group operates. The directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the Group’s control. Forward looking statements are not guarantees of future performance. Even if the Group’s actual results of operations, financial condition and the development of the industries in which the Group operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.